George H. Talbot

10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America

Helen W. Boucher, George H. Talbot, Daniel K. Benjamin et al. · Clinical Infectious Diseases · 2013 · 692 citations · Full text

Systemic Antibiotics, Antimicrobial Chemotherapy, Antibiotic Resistance +19

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

Helen W. Boucher, Mark Wilcox, George H. Talbot et al. · New England Journal of Medicine · 2014 · 420 citations · Full text

Risk factors for nosocomial candidemia: A case-control study in adults without leukemia

James L. Bross, George H. Talbot, Greg Maislin et al. · The American Journal of Medicine · 1989 · 276 citations

Clinical Epidemiology, Clinical Mycology, Risk Factors +4

Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure Infection

G. Ralph Corey, Mark H. Wilcox, George H. Talbot et al. · Clinical Infectious Diseases · 2010 · 236 citations

The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium

Robert C. Moellering, Peter K. Linden, J. F. Reinhardt et al. · Journal of Antimicrobial Chemotherapy · 1999 · 220 citations

Antimicrobial Susceptibility, Health Sciences, Antibiotics +13